Literature DB >> 19545536

Photoaffinity labeling the agonist binding domain of alpha4beta4 and alpha4beta2 neuronal nicotinic acetylcholine receptors with [(125)I]epibatidine and 5[(125)I]A-85380.

Ayman K Hamouda1, Xiaochun Jin, Mitesh Sanghvi, Shouryadeep Srivastava, Akash Pandhare, Phaneendra K Duddempudi, Joe Henry Steinbach, Michael P Blanton.   

Abstract

The development of nicotinic acetylcholine receptor (nAChR) agonists, particularly those that discriminate between neuronal nAChR subtypes, holds promise as potential therapeutic agents for many neurological diseases and disorders. To this end, we photoaffinity labeled human alpha4beta2 and rat alpha4beta4 nAChRs affinity-purified from stably transfected HEK-293 cells, with the agonists [(125)I]epibatidine and 5[(125)I]A-85380. Our results show that both agonists photoincorporated into the beta4 subunit with little or no labeling of the beta2 and alpha4 subunits respectively. [(125)I]epibatidine labeling in the beta4 subunit was mapped to two overlapping proteolytic fragments that begin at beta4V102 and contain Loop E (beta4I109-P120) of the agonist binding site. We were unable to identify labeled amino acid(s) in Loop E by protein sequencing, but we were able to demonstrate that beta4Q117 in Loop E is the principal site of [(125)I]epibatidine labeling. This was accomplished by substituting residues in the beta2 subunit with the beta4 homologs and finding [(125)I]epibatidine labeling in beta4 and beta2F119Q subunits with little, if any, labeling in alpha4, beta2, or beta2S113R subunits. Finally, functional studies established that the beta2F119/beta4Q117 position is an important determinant of the receptor subtype-selectivity of the agonist 5I-A-85380, affecting both binding affinity and channel activation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19545536      PMCID: PMC2744590          DOI: 10.1016/j.bbamem.2009.06.012

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  27 in total

Review 1.  Nicotinic receptors at the amino acid level.

Authors:  P J Corringer; N Le Novère; J P Changeux
Journal:  Annu Rev Pharmacol Toxicol       Date:  2000       Impact factor: 13.820

2.  Refined structure of the nicotinic acetylcholine receptor at 4A resolution.

Authors:  Nigel Unwin
Journal:  J Mol Biol       Date:  2005-01-25       Impact factor: 5.469

Review 3.  Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations.

Authors:  Anders A Jensen; Bente Frølund; Tommy Liljefors; Povl Krogsgaard-Larsen
Journal:  J Med Chem       Date:  2005-07-28       Impact factor: 7.446

4.  Role of the agonist binding site in up-regulation of neuronal nicotinic alpha4beta2 receptors.

Authors:  Masashi Kishi; Joe Henry Steinbach
Journal:  Mol Pharmacol       Date:  2006-09-11       Impact factor: 4.436

5.  The conformation of acetylcholine at its target site in the membrane-embedded nicotinic acetylcholine receptor.

Authors:  P T F Williamson; A Verhoeven; K W Miller; B H Meier; A Watts
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-07       Impact factor: 11.205

6.  5-I A-85380 and TC-2559 differentially activate heterologously expressed alpha4beta2 nicotinic receptors.

Authors:  Ruud Zwart; Lisa M Broad; Qian Xi; Martin Lee; Mirko Moroni; Isabel Bermudez; Emanuele Sher
Journal:  Eur J Pharmacol       Date:  2006-04-05       Impact factor: 4.432

7.  Identifying the lipid-protein interface of the alpha4beta2 neuronal nicotinic acetylcholine receptor: hydrophobic photolabeling studies with 3-(trifluoromethyl)-3-(m-[125I]iodophenyl)diazirine.

Authors:  Ayman K Hamouda; Mitesh Sanghvi; David C Chiara; Jonathan B Cohen; Michael P Blanton
Journal:  Biochemistry       Date:  2007-11-10       Impact factor: 3.162

8.  Defining nicotinic agonist binding surfaces through photoaffinity labeling.

Authors:  Motohiro Tomizawa; David Maltby; Katalin F Medzihradszky; Nanjing Zhang; Kathleen A Durkin; Jack Presley; Todd T Talley; Palmer Taylor; Alma L Burlingame; John E Casida
Journal:  Biochemistry       Date:  2007-07-06       Impact factor: 3.162

9.  Neuroactive steroids and human recombinant rho1 GABAC receptors.

Authors:  Wenjun Li; Xiaochun Jin; Douglas F Covey; Joe Henry Steinbach
Journal:  J Pharmacol Exp Ther       Date:  2007-07-17       Impact factor: 4.030

10.  Nicotine binding to brain receptors requires a strong cation-pi interaction.

Authors:  Xinan Xiu; Nyssa L Puskar; Jai A P Shanata; Henry A Lester; Dennis A Dougherty
Journal:  Nature       Date:  2009-03-01       Impact factor: 49.962

View more
  6 in total

1.  NMR structures of the transmembrane domains of the α4β2 nAChR.

Authors:  Vasyl Bondarenko; David Mowrey; Tommy Tillman; Tanxing Cui; Lu Tian Liu; Yan Xu; Pei Tang
Journal:  Biochim Biophys Acta       Date:  2012-02-14

2.  A portable site: a binding element for 17β-estradiol can be placed on any subunit of a nicotinic α4β2 receptor.

Authors:  Xiaochun Jin; Joe Henry Steinbach
Journal:  J Neurosci       Date:  2011-03-30       Impact factor: 6.167

3.  Defining the putative inhibitory site for a selective negative allosteric modulator of human α4β2 neuronal nicotinic receptors.

Authors:  Brandon J Henderson; Tatiana F González-Cestari; Bitna Yi; Ryan E Pavlovicz; R Thomas Boyd; Chenglong Li; Stephen C Bergmeier; Dennis B McKay
Journal:  ACS Chem Neurosci       Date:  2012-05-25       Impact factor: 4.418

4.  Interacting amino acid replacements allow poison frogs to evolve epibatidine resistance.

Authors:  Rebecca D Tarvin; Cecilia M Borghese; Wiebke Sachs; Juan C Santos; Ying Lu; Lauren A O'Connell; David C Cannatella; R Adron Harris; Harold H Zakon
Journal:  Science       Date:  2017-09-22       Impact factor: 47.728

Review 5.  Naturally-expressed nicotinic acetylcholine receptor subtypes.

Authors:  Jie Wu; Ronald J Lukas
Journal:  Biochem Pharmacol       Date:  2011-07-20       Impact factor: 5.858

6.  Pharmacology of structural changes at the GABA(A) receptor transmitter binding site.

Authors:  Gustav Akk; Ping Li; John Bracamontes; Mengya Wang; Joe Henry Steinbach
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.